Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703919 | 0.79 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3CXCR4PDE10A | |
| SCHEMBL5580038 | 0.78 | NISCH (0.32) | NISCH | |
| SCHEMBL17459374 | 0.64 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL3699653 | 0.64 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3CXCR4OPRM1 | |
| SCHEMBL20198840 | 0.64 | CCR1 (0.50) | MAPTPDE10AOPRM1OPRL1 | |
| SCHEMBL14186232 | 0.62 | DRD4 (0.46) | CXCR4PDE10AOPRM1OPRL1 | |
| SCHEMBL3740802 | 0.61 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL21037741 | 0.59 | DRD4 (0.48) | — | |
| SCHEMBL3699707 | 0.59 | SLC6A4 (0.43) | SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL17459363 | 0.59 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | SLC6A2 432/4885SLC6A4 1726/4885SLC6A3 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.